BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Diabetes

Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...

April 01, 2025 | News

Singapore’s NUS Researchers Develop Dual Microneedle Technologies to Accelerate Healing of Diabetic Wounds

Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by persistent inflammati...

March 27, 2025 | News

MicuRx’s MRX-4 and Contezolid Show Favorable Safety and Efficacy in Phase III Trial for Diabetic Foot Infections

Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial, recommending continued pro...

February 26, 2025 | News

BioMed X Launches Research Hub in Barbados to Advance Cardiometabolic Disease Treatment for Individuals of African Descent

BioMed X Institute, in collaboration with the Government of Barbados and the European Commission, is launching BioMed X Barbados, a new rese...

February 21, 2025 | News

ORA’s Hybrid Model Reshapes Obesity Care: Dr. Ben Ng on Bridging Telehealth and In-Person Treatment

With obesity-related chronic diseases on the rise in Singapore, ORA Group has introduced a pioneering hybrid weight management model, blend...

February 19, 2025 | Expert Insight

ORA Group Introduces Singapore’s First Hybrid Weight Management Care to Tackle Rising Obesity Rates

ORA Group (ORA), a leading Singapore-based health and wellness company known for its cutting-edge telehealth platforms andSons and OVA, has unveiled a grou...

February 12, 2025 | News

Genentech Secures FDA Approval for Susvimo the First Long-Lasting Treatment for Diabetic Macular Edema

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME...

February 05, 2025 | News

Helix Introduces Clinico-Genomic Dataset of 15,000 GLP-1 Agonist Patients to Advance Precision Medicine

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon...

February 04, 2025 | News

Aarian Health Appoints Thomas Keller as Business Director to Drive Innovation and Growth

Aarian Health is thrilled to announce the appointment of Thomas Keller as our new Business Director. With over 20 years of experience across the pharmaceut...

January 22, 2025 | News

Regor’s Oral GLP-1RA RGT-075 Shows 5% Placebo-Adjusted Weight Loss in Phase 2a Trial with Strong Safety Profile

Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no ...

January 13, 2025 | News

Glooko and Hedia Launch Interoperable Solution for Advanced Diabetes Management in the UK

Glooko, Inc. and Hedia, announced the launch of their interoperable solution, which combines connected care, remote patient monitoring, and digital th...

January 09, 2025 | News

Health2Sync's Vision for Diabetes Care: Transforming Outcomes Through Technology and Partnerships

In an exclusive interview with BioPharma APAC, Ed Deng, Co-founder and CEO of Health2Sync, delves into the transformative impact of their collabora...

December 24, 2024 | Interaction

Taiwan’s Health2Sync Partners with Western Sydney Diabetes to Transform Diabetes Care Through Digital Innovation

Health2Sync, Asia’s leading digital health solutions provider, announced a new partnership with Western Sydney Diabetes . This collaboration aims to ...

December 18, 2024 | News

Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production

The investment will benefit millions of patients worldwide, boosting the production of the company's medicines, including those for diabetes and obesity&nb...

December 06, 2024 | News

Stay Connected